RxDoctor Payments Data

James Maddux, MD

Interventional Cardiology · Missoula, MTNPI 1942237326

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (35.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Abbott accounts for 66.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $8,587 and has fallen 76.7% since, to $2,003 in 2025.

$26,001in general payments, 2019–2025

Across 262 payments — averaging $99.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$17K
  • Edwards Lifesciences$4K
  • Medtronic$2K
  • Boston Scientific$1K
  • Abiomed$362
  • Shockwave Medical, Inc$185
  • plus $192 from 5 others
$414,471in research payments, 2019–2025

Across 171 payments — averaging $2423.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$211K
  • Abbott$138K
  • Medtronic$51K
  • Boston Scientific$15K

What the payments were for

  • Consulting fees$8,30032%
  • Travel & lodging$8,35432%
  • Food & beverage$9,33536%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,001 in reported general payments places this provider in the 65th percentile of 22 interventional cardiology providers in Montana.

See all interventional cardiology providers in Montana

Medicare billing

Part B allowed, 2024
$312,081
Medicare patients
1,086
Services billed
2,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten16$124,021
EliquisApixaban100$102,639
Repatha SureclickEvolocumab43$48,957
XareltoRivaroxaban12$18,443
Atorvastatin Calcium281$3,645
Metoprolol Succinate162$2,813
ClopidogrelClopidogrel Bisulfate166$2,113
Prasugrel Hcl34$1,753
Lisinopril156$1,283
Losartan Potassium122$1,267
Isosorbide Mononitrate ErIsosorbide Mononitrate87$1,157
Potassium Chloride42$1,084
Carvedilol93$927
Rosuvastatin Calcium100$892
Furosemide122$755

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →